Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 6/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.39 |
| ▸ | CDK2 | P24941 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | TYK2 | P29597 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174445 | 0.84 | CCNE2 (0.44) | CCNE2CCNE1CDK2ALDH1A1GAA | |
| SCHEMBL174033 | 0.83 | CCNE2 (0.39) | CCNE2CCNE1CDK2ALDH1A1GAA | |
| SCHEMBL165657 | 0.82 | JAK2 (0.56) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL162857 | 0.82 | JAK2 (0.43) | JAK2CYP3A4CYP2C8CYP2C9JAK1 | |
| SCHEMBL159128 | 0.81 | CCNE2 (0.40) | CCNE2CCNE1CDK2ALDH1A1GAA | |
| SCHEMBL159127 | 0.79 | JAK2 (0.56) | CCNE2CCNE1CDK2ALDH1A1GAA | |
| SCHEMBL174321 | 0.77 | CCNE2 (0.41) | CCNE2CCNE1CDK2ALDH1A1GAA | |
| SCHEMBL160631 | 0.76 | GSK3A (0.56) | CCNE2CCNE1CDK2ALDH1A1GAA | |
| SCHEMBL161223 | 0.74 | CCNE2 (0.36) | CCNE2CCNE1CDK2ALDH1A1GAA | |
| SCHEMBL162466 | 0.74 | METAP1 (0.38) | CCNE2CCNE1CDK2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | claimed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | claimed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | claimed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, TYK2 | CCNE2 3680/4885CCNE1 3931/4885CDK2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.